This Insight Brief explores the transformative impact of cell and gene therapies (CAGTs) on clinical practice and patient care, highlighting the surge in FDA approvals and global trials. It delves into the evolving regulatory landscape, emphasizing the proactive efforts of the FDA and international bodies to adapt to CAGT innovations. 

Read the Insight Brief authored by experts from IQVIA Biotech and IQVIA addressing the clinical development challenges of CAGTs, including trial design, patient identification, and long-term follow-up, while showcasing our comprehensive solutions and expertise in navigating this dynamic field. 

Read the blog article Transforming Medicine: Strategies in Cell and Gene Therapy Development.